Home
QTTB
QTTB News

Latest Q32 Bio Inc. Common Stock (QTTB) News on June 28, 2025

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

PR Newswire

3 days ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

TipRanks

4 days ago

Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary

OXB completes acquisition of remaining stake in US subsidiary

GlobeNewswire

5 days ago

OXB completes acquisition of remaining stake in US subsidiary

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire

2 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

PR Newswire

2 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

PR Newswire

2 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire

4 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

PR Newswire

4 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

PR Newswire

4 months ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

PR Newswire

4 months ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

PR Newswire

5 months ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

PR Newswire

5 months ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio price target lowered to $20 from $80 at Oppenheimer

TipRanks

7 months ago

Q32 Bio price target lowered to $20 from $80 at Oppenheimer

Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Investor's Business Daily

7 months ago

Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

PR Newswire

7 months ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%

Simply Wall St.

7 months ago

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire

8 months ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

PR Newswire

8 months ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

PR Newswire

8 months ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

PR Newswire

10 months ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

PR Newswire

a year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

PR Newswire

a year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake

Simply Wall St.

a year ago

Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

Simply Wall St.

a year ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

a year ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Simply Wall St.

a year ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled

Motley Fool

a year ago

3 Mistakes That Can Get Your Costco Membership Canceled

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire

a year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

PR Newswire

a year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Share on Social Networks: